News
CNSP
3.980
-4.14%
-0.172
Weekly Report: what happened at CNSP last week (0615-0619)?
Weekly Report · 6d ago
Weekly Report: what happened at CNSP last week (0608-0612)?
Weekly Report · 06/15 10:26
Weekly Report: what happened at CNSP last week (0601-0605)?
Weekly Report · 06/08 10:21
Weekly Report: what happened at CNSP last week (0525-0529)?
Weekly Report · 06/01 10:26
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 05/26 12:06
Weekly Report: what happened at CNSP last week (0518-0522)?
Weekly Report · 05/25 10:30
Insider Boost: CNS Pharmaceuticals Director Quietly Ramps Up His Stake
TipRanks · 05/21 02:09
CNS Pharma director Faith L. Charles buys 7,100 shares for $34,000
PUBT · 05/20 13:04
CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders
TipRanks · 05/19 21:01
Weekly Report: what happened at CNSP last week (0511-0515)?
Weekly Report · 05/18 10:29
Maxim Group Sticks to Their Buy Rating for CNS Pharmaceuticals (CNSP)
TipRanks · 05/15 13:26
CNS Pharmaceuticals reports Q1 EPS ($7.30) vs. ($18.93) last year
TipRanks · 05/14 16:25
CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months
TipRanks · 05/14 16:22
CNS Pharmaceuticals Q1 EPS $(7.30) Misses $(5.37) Estimate
Benzinga · 05/14 12:28
CNS Pharmaceuticals reports Q1 results
Seeking Alpha · 05/14 12:06
CNS Pharmaceuticals Q1 net loss widens to $4.94 million from year-ago quarter
PUBT · 05/14 11:56
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 05/11 17:05
Weekly Report: what happened at CNSP last week (0504-0508)?
Weekly Report · 05/11 10:26
What's Going On With CNS Pharmaceuticals Stock On Wednesday?
Benzinga · 05/06 13:51
3 Penny Stocks to Watch Now, 5/5/26
TipRanks · 05/05 16:22
More
Webull provides a variety of real-time CNSP stock news. You can receive the latest news about CNS Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About CNSP
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.